BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27190083)

  • 1. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
    Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S
    Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
    Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
    J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
    Toyoda F; Tanaka Y; Ota A; Shimmura M; Kinoshita N; Takano H; Matsumoto T; Tsuji J; Kakehashi A
    J Diabetes Res; 2014; 2014():672590. PubMed ID: 25215304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules.
    Okayama N; Omi H; Okouchi M; Imaeda K; Kato T; Akao M; Imai S; Shimizu M; Fukutomi T; Itoh M
    J Diabetes Complications; 2002; 16(5):321-6. PubMed ID: 12200074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
    Kashima K; Sato N; Sato K; Shimizu H; Mori M
    Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of nitric oxide production by aldose reductase inhibitor in human endothelial cells cultured in high-glucose medium.
    Okuda Y; Kawashima K; Suzuki S; Asakura Y; Asano M; Tsurumaru K; Dai H; Tachi Y; Bannai C; Saitoh M; Yamashita K
    Life Sci; 1997; 60(3):PL53-6. PubMed ID: 9000650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protective effect of epalrestat against high glucose-induced endothelial cell injuries].
    Wang F; Hong Q; Liu G
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(7):940-3. PubMed ID: 22820572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
    Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
    Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.
    Matsumoto T; Ono Y; Kurono M; Kuromiya A; Nakamura K; Bril V
    J Pharmacol Sci; 2008 Jul; 107(3):231-7. PubMed ID: 18635918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations.
    Huang Z; Hong Q; Zhang X; Xiao W; Wang L; Cui S; Feng Z; Lv Y; Cai G; Chen X; Wu D
    Cell Commun Signal; 2017 Jan; 15(1):3. PubMed ID: 28057038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective Effects of Novel Substituted Triazinoindole Inhibitors of Aldose Reductase and Epalrestat in Neuron-like PC12 Cells and BV2 Rodent Microglial Cells Exposed to Toxic Models of Oxidative Stress: Comparison with the Pyridoindole Antioxidant Stobadine.
    Elmazoglu Z; Prnova MS; Stefek M; Ceylan AF; Aschner M; Rangel-López E; Santamaria A; Karasu C
    Neurotox Res; 2021 Jun; 39(3):588-597. PubMed ID: 33713301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
    He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
    Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
    Sobajima H; Aoki T; Sassa H; Suzuki T; Taniko K; Makino M; Mizuno K; Suzuki T
    Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
    Giannoukakis N
    Expert Opin Investig Drugs; 2008 Apr; 17(4):575-81. PubMed ID: 18363521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells.
    Tanagala KKK; Baba AB; Kowshik J; Reddy GB; Nagini S
    Anticancer Agents Med Chem; 2018; 18(14):2042-2052. PubMed ID: 30062975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.